Contact us to learn more about

our Premium Content: News alerts, weekly reports and conference planners

GENE:

RAD51C (RAD51 paralog C)

Contact us to learn more about our Premium Content:

News alerts, weekly reports and conference planners

Entrez ID:

Related tests:

‹

›

RAD51C mutation	Prostate Cancer	RAD51C mutation	Prostate Cancer	olaparib Sensitive: A2 - Guideline olaparib Sensitive : A2	olaparib Sensitive: A2 - Guideline olaparib Sensitive : A2
RAD51C mutation	Ovarian Cancer	RAD51C mutation	Ovarian Cancer	rucaparib Sensitive: B - Late Trials rucaparib Sensitive : B	rucaparib Sensitive: B - Late Trials rucaparib Sensitive : B
RAD51C mutation	Ovarian Cancer	RAD51C mutation	Ovarian Cancer	olaparib Sensitive: B - Late Trials olaparib Sensitive : B	olaparib Sensitive: B - Late Trials olaparib Sensitive : B
RAD51C mutation	Small Cell Lung Cancer	RAD51C mutation	Small Cell Lung Cancer	olaparib Sensitive: C2 – Inclusion Criteria olaparib Sensitive : C2	olaparib Sensitive: C2 – Inclusion Criteria olaparib Sensitive : C2
RAD51C mutation	HER2 Negative Breast Cancer	RAD51C mutation	HER2 Negative Breast Cancer	durvalumab Sensitive: C2 – Inclusion Criteria durvalumab Sensitive : C2	durvalumab Sensitive: C2 – Inclusion Criteria durvalumab Sensitive : C2
HR positive + RAD51C amplification	HER2 Negative Breast Cancer	HR positive + RAD51C amplification	HER2 Negative Breast Cancer	palbociclib Resistant: C3 – Early Trials palbociclib Resistant : C3	palbociclib Resistant: C3 – Early Trials palbociclib Resistant : C3
RAD51C mutation	Peritoneal Cancer	RAD51C mutation	Peritoneal Cancer	rucaparib Sensitive: C3 – Early Trials rucaparib Sensitive : C3	rucaparib Sensitive: C3 – Early Trials rucaparib Sensitive : C3
RAD51C mutation	Fallopian Tube Cancer	RAD51C mutation	Fallopian Tube Cancer	rucaparib Sensitive: C3 – Early Trials rucaparib Sensitive : C3	rucaparib Sensitive: C3 – Early Trials rucaparib Sensitive : C3
RAD51C expression	Germ Cell Tumors	RAD51C expression	Germ Cell Tumors	olaparib Resistant: D – Preclinical olaparib Resistant : D	olaparib Resistant: D – Preclinical olaparib Resistant : D